The non-infectious effects of COVID-19 were fierce with the weakest: What lessons did we learn?

Código QR

The non-infectious effects of COVID-19 were fierce with the weakest: What lessons did we learn?

Guardado en:

Detalles Bibliográficos
Autores principales:	Aline Meza-Ramos, Eduard Guasch
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/72a24147e34a449c959688b5e30f4957
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Remote Clinics and Investigations in Arrhythmia Services: What Have We Learnt During Coronavirus Disease 2019?
por: Shohreh Honarbakhsh, et al.
Publicado: (2021)

How did the updated hemodynamic definitions affect the frequency of pulmonary hypertension in patients with systemic sclerosis?
por: Alper Sarı, et al.
Publicado: (2021)

Heart Rate Variability and Cardiovascular Fitness: What We Know so Far
por: Souza HCD, et al.
Publicado: (2021)

Moderate Aortic Stenosis: What is it and When Should We Intervene?
por: Sveeta Badiani, et al.
Publicado: (2021)

Relationship between frontal QRS-T duration and the severity of coronary artery disease in who were non-diabetic and had stable angina pectoris
por: Halil Akın, et al.
Publicado: (2021)

Coronavirus Disease 2019: Where are we and Where are we Going? Intersections Between Coronavirus Disease 2019 and the Heart
por: Emilia D’Elia, et al.
Publicado: (2020)

What is your diagnosis?
por: Uğur Nadir Karakulak, et al.
Publicado: (2021)

What is your diagnosis?
por: Yavuzer Koza, et al.
Publicado: (2021)

Anticoagulation in Peripheral Artery Disease: Are We There Yet?
por: Alessandro Cannavale, et al.
Publicado: (2020)

Rhythm Control in AF: Have We Reached the Last Frontier?
por: Gheorghe-Andrei Dan
Publicado: (2019)

Diabetes and mortality in patients with COVID-19: Are we missing the link?
por: Marco Toselli2, et al.
Publicado: (2021)

Meditation and Cardiovascular Health: What is the Link?
por: Sebastian Schnaubelt, et al.
Publicado: (2019)

The ISCHEMIA Trial: What is the Message for the Interventionalist?
por: Emmanuel Ako, et al.
Publicado: (2021)

Behavioural Interventions to Reduce Cardiovascular Risk: Where Do We Stand?
por: Gianluigi Savarese
Publicado: (2019)

Thrombosis in COVID-19: We still need to learn a lot
por: Cem Barçın
Publicado: (2021)

Cerebrovascular ischemic event - what about the coronaries
por: Joseph C. Lee, et al.
Publicado: (2021)

Sleep Apnoea and AF: Where Do We Stand? Practical Advice for Clinicians
por: Suneet Mittal, et al.
Publicado: (2021)

What Cannot be Missed: Must-read Papers, 2018
por: Demosthenes G Katritsis
Publicado: (2019)

What Cannot Be Missed: Important Publications on Electrophysiology in 2019
por: Andrew Grace, et al.
Publicado: (2020)

What Cannot Be Missed: Important Publications on Electrophysiology in 2020
por: Sanjiv M Narayan, et al.
Publicado: (2021)

Personalised Approaches to Improving the Effect of Anti-platelet Agents: Where Do We Stand?
por: Lucas C Godoy, et al.
Publicado: (2019)

What is the Real Message of the ISCHEMIA Trial from a Clinician’s Perspective?
por: Islam Y Elgendy, et al.
Publicado: (2020)

Evaluation of low gradient severe aortic stenosis: should we change our outlook in the analysis of clinical data?
por: Ivan Corazza, et al.
Publicado: (2021)

Using Pharmacogenetic Testing to Tailor Warfarin Therapy: The Singapore Experience and What the Future Holds
por: Grace Shu-wen Chang, et al.
Publicado: (2020)

Non‐invasive isthmus identification of complex arrhythmias in congenital heart disease
por: Levio Quinto, et al.
Publicado: (2021)

Electrophysiology’s Identity Crisis: What our Clinical Trials Do and Do Not Say About Us
por: David J Callans, et al.
Publicado: (2020)

Reduced exercise capacity in the adult with repaired tetralogy of Fallot: More evidence. Now what to do?
por: Rose Tompkins, et al.
Publicado: (2021)

Aortic dissection type 1, windsock sign, neglected lead, and Kounis syndrome: What a coincidence!
por: Nicholas G. Kounis, et al.
Publicado: (2021)

Novel Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease: What Cardiologists and Diabetologists Should Know
por: Felipe Martínez
Publicado: (2021)

What is Standard Dose of Rivaroxaban in Elderly Asian Patients with Atrial Fibrillation: 20ms versus. 15mg?
por: Sung Soo Kim MD, et al.
Publicado: (2021)

What cardiologists need to know about cardiovascular magnetic resonance (CMR)
por: J. Cameron Bridgman, et al.
Publicado: (2017)

What is the Real Message of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial for Academic and Practising Cardiologists?
por: Kreton Mavromatis, et al.
Publicado: (2020)

Optimal paediatric cardiac services in South Africa – what do we need?
por: A.M. Cilliers, et al.
Publicado: (2017)

Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip
por: Kimberly Atianzar, et al.
Publicado: (2019)

Why do we need to be vigilant over myocardial thickening in oncology patients? Lessons from a case
por: Çağdaş Topel, et al.
Publicado: (2021)

TAVI for Pure Native Aortic Regurgitation: Are We There Yet?
por: Eduardo A Arias, et al.
Publicado: (2019)

Diabetic Cardiomyopathy: Five Major Questions with Simple Answers
por: Miguel Alejandro Rodriguez-Ramos
Publicado: (2019)

Lessons from the Heart of Soweto Study and future directions
por: Sandra Pretorius, et al.
Publicado: (2017)

Post-Acute Sequelae of COVID-19 and Cardiovascular Autonomic Dysfunction: What Do We Know?
por: Giandomenico Bisaccia, et al.
Publicado: (2021)

What an Interventionalist Needs to Know About MI with Non-obstructive Coronary Arteries
por: Robert Sykes, et al.
Publicado: (2021)